RxDoctor Payments Data

Chandana Reddy, DO

Family Medicine · Allen, TXNPI 1700851128

Payments from drug & device makers

$2,677in general payments, 2019–2025

Across 133 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$883
  • Sanofi$321
  • Lilly USA, LLC$237
  • Pfizer$198
  • Genentech USA, Inc.$149
  • AstraZeneca$101
  • plus $787 from 16 others

What the payments were for

  • Food & beverage$2,677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,677 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,371
Medicare patients
132
Services billed
1,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$54,484
JardianceEmpagliflozin17$16,036
JanuviaSitagliptin Phosphate12$10,965
Levothyroxine Sodium173$1,714
Atorvastatin Calcium147$1,302
SynthroidLevothyroxine Sodium12$984
Estradiol32$820
FenofibrateFenofibrate Nanocrystallized20$658
Simvastatin61$577
Lisinopril97$572
Albuterol Sulfate HfaAlbuterol Sulfate20$546
Omeprazole46$496
Metoprolol Succinate33$489
Pantoprazole Sodium38$454
Rosuvastatin Calcium43$439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$47$54,48443 claims
Boehringer IngelheimJardiance$99$16,03617 claims
MerckJanuvia$64$10,96512 claims
AbbVieSynthroid$81$98412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →